Date: 2015-03-24
Type of information: IPO
Company: Cellectis (France)
Investors:
Amount: $ 212.3 million
Funding type: IPO
Planned used:
Others: * On March 24, 2015, Cellectis, a pioneering gene-editing company employing proprietary technologies to develop best-in-class
products in the emerging field of immuno-oncology, announced the pricing of its initial public offering of 5,500,000 American Depositary Shares (ADSs), each representing an ordinary share of the Company, at a price to the public of $41.50 per ADS. The ADSs are expected to begin trading on the Nasdaq Global Market under the ticker symbol “CLLS” on Wednesday, March 25, 2015. In addition, Cellectis has granted the underwriters a 30-day option to purchase up to an additional 825,000 ADSs.
BofA Merrill Lynch, Jefferies and Piper Jaffray & Co. are acting as joint book-running managers for the offering. Oppenheimer & Co. and Trout Capital are acting as co-managers for the offering.
Therapeutic area:
